Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 141 results for copd

  1. Mucolytic therapy:- In people with COPD, does mucolytic drug therapy prevent exacerbations in comparison with placebo and other therapies?

    Recommendation ID NG115/11 Question Mucolytic therapy:- In people with COPD, does mucolytic drug therapy prevent exacerbations in...

    Research recommendation
    Published
    13 February 2019

  2. Multidimensional assessment of outcomes- How can the individual factors associated with COPD prognosis (collected from a range of sources including primary care, imaging and pulmonary rehabilitation results) be combined into a multidimensional analysis that provides accurate and useful information on prognosis?

    Multidimensional assessment of outcomes- How can the individual factors associated with COPD prognosis (collected from a range of...

    Research recommendation
    Published
    6 February 2019

  3. Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of seasonal versus continuous prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    seasonal versus continuous prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations? Any explanatory...

    Research recommendation
    Published
    13 February 2019

  4. Prophylactic antibiotics for preventing exacerbations: - What is the long-term clinical and cost effectiveness of prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    and cost effectiveness of prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations? Any explanatory...

    Research recommendation
    Published
    13 February 2019

  5. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

    General practice indicators suitable for use in QOF
    Published
    31 July 2019

  6. VIDAvision for lung volume analysis in emphysema (MIB148)

    NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .

    Medtech innovation briefing
    Published
    5 June 2018

  7. Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of different antibiotics, doses and regimens of prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    antibiotics, doses and regimens of prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations? Any...

    Research recommendation
    Published
    13 February 2019

  8. Lung volume reduction surgery for advanced emphysema (IPG114)

    Evidence-based recommendations on lung volume reduction surgery for treating advanced emphysema. This involves removing damaged lung tissue using a special stapling device, a laser, or both.

    Interventional procedures guidance
    Published
    23 February 2005
    View recommendations

    Sections for IPG114

  9. NICE real-world evidence framework (ECD9)

    The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  10. Inhaled corticosteroid responsiveness:- What features predict inhaled corticosteroid responsiveness most accurately in people with COPD?

    predict inhaled corticosteroid responsiveness most accurately in people with COPD? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    6 February 2019

  11. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (DG62)

    Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome

    Diagnostics guidance
    Published
    19 December 2024
    View recommendations

    Sections for DG62

  12. Evidence on the safety and efficacy of endobronchial nerve ablation for chronic obstructive pulmonary disease (COPD) is inadequate in quantity. Therefore, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page. Further research should be randomised controlled trials comparing the procedure with sham treatment. It should report details of patient selection, and short and long-term functional outcomes including lung functional outcomes, quality of life and patient-reported outcomes, incidence of exacerbations and hospital admissions, and all adverse events.

    safety and efficacy of endobronchial nerve ablation for chronic obstructive pulmonary disease (COPD) is inadequate in...

    Research recommendation
    Published
    7 January 2022

  13. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  14. Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home) (QS210)

    This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.

    Quality standard
    Published
    31 October 2023
    View quality statements

    Sections for QS210

  15. Pulmonary rehabilitation during hospital admission:- In people with COPD, does pulmonary rehabilitation during hospital admission for exacerbation and/or in the early recovery period (within 1 month of an exacerbation) improve quality of life and reduce hospitalisations and exacerbations compared with a later (defined as after 1 month)pulmonary rehabilitation programme, and in which groups is it most clinically and cost effective?

    Question Pulmonary rehabilitation during hospital admission:- In people with COPD, does pulmonary rehabilitation during hospital...

    Research recommendation
    Published
    6 February 2019